MX2008013829A - Uso de compuestos de la formula a-r-x o sus sales farmaceuticas tolerables para producir una preparacion farmaceutica. - Google Patents

Uso de compuestos de la formula a-r-x o sus sales farmaceuticas tolerables para producir una preparacion farmaceutica.

Info

Publication number
MX2008013829A
MX2008013829A MX2008013829A MX2008013829A MX2008013829A MX 2008013829 A MX2008013829 A MX 2008013829A MX 2008013829 A MX2008013829 A MX 2008013829A MX 2008013829 A MX2008013829 A MX 2008013829A MX 2008013829 A MX2008013829 A MX 2008013829A
Authority
MX
Mexico
Prior art keywords
formula
manufacture
radical
compounds
pharmaceutical preparations
Prior art date
Application number
MX2008013829A
Other languages
English (en)
Inventor
Dieter Mueller-Enoch
Thomas Haehner
Original Assignee
Dieter Mueller-Enoch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dieter Mueller-Enoch filed Critical Dieter Mueller-Enoch
Publication of MX2008013829A publication Critical patent/MX2008013829A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un compuesto de la fórmula A-R-X o sales farmacéuticamente aceptables de esta se pueden usar para producir una preparación farmacéutica que sirve para prevenir o tratar enfermedades cancerígenas, secuelas patológicas del abuso del alcohol, hepatitis viral, esteato-hepatitis, pancreatitis aguda y crónica, enfermedades renales tóxicas, resistencia hepática a la insulina en diabetes mellitus, daños al hígado por Morbus Wilson y siderosis, daños de reperfusión por isquemia, como antídoto contra venenos del entorno e intoxicación por medicamentos, para prolongar el tiempo de permanencia de los medicamentos en el organismo, o para combatir los efectos tóxicos secundarios en la administración de agentes de quimioterapía. En la fórmula R es un radial hidrocarburo-C6 a C40 alifático o aromático el cual comprende un extremo A hidrofilo, y X es un radical que comprende al menos un par de electrones libres de un átomo de carbono o heteroátomo y/o electrones p.
MX2008013829A 2006-04-28 2007-04-27 Uso de compuestos de la formula a-r-x o sus sales farmaceuticas tolerables para producir una preparacion farmaceutica. MX2008013829A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006019906A DE102006019906A1 (de) 2006-04-28 2006-04-28 Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptable Salze zur Herstellung einer pharmazeutischen Zubereitung
PCT/DE2007/000768 WO2007124734A2 (de) 2006-04-28 2007-04-27 Verbindungen a-r-x zur herstellung von pharmazeutischen zubereitungen

Publications (1)

Publication Number Publication Date
MX2008013829A true MX2008013829A (es) 2009-04-03

Family

ID=38462536

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013829A MX2008013829A (es) 2006-04-28 2007-04-27 Uso de compuestos de la formula a-r-x o sus sales farmaceuticas tolerables para producir una preparacion farmaceutica.

Country Status (15)

Country Link
US (1) US8153676B2 (es)
EP (1) EP2023911B1 (es)
JP (1) JP2009535309A (es)
KR (1) KR101113436B1 (es)
CN (1) CN101478960B (es)
AU (1) AU2007246023B2 (es)
BR (1) BRPI0710796A2 (es)
CA (1) CA2650577C (es)
DE (2) DE102006019906A1 (es)
HK (1) HK1134902A1 (es)
IL (1) IL194961A0 (es)
MX (1) MX2008013829A (es)
RU (3) RU2477275C1 (es)
UA (1) UA93709C2 (es)
WO (1) WO2007124734A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007051339A1 (de) 2007-10-26 2009-04-30 Müller-Enoch, Dieter, Prof. Dr. Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptablen Salze zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung und zur Vorbeugung von Dyslipidämien
DE102010012225A1 (de) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Kosmetikum
DE102010012234A1 (de) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Pharmazeutisches Kombinationspräparat
DE102010012224A1 (de) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Pharmazeutisches Präparat
DE102010012232A1 (de) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Irnidazole
DE102010012235A1 (de) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Imidazole
DE102010012226A1 (de) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Pharmazeutisches Kombinationspräparat
DE102010012223A1 (de) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Pharmazeutisches Präparat
DE102010012233A1 (de) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Imidazole
BR112013033309B1 (pt) 2011-06-24 2022-07-05 Gri Bio, Inc Uso de tazaroteno e método in vitro para inibição de ativação de células nkt tipo i
DE102011112103A1 (de) 2011-09-02 2013-03-07 Acrovis Biostructures Gmbh Pharmazeutisches Präparat
DE102012018052A1 (de) 2011-09-21 2013-03-21 Acrovis Biostructures Gmbh Pharmazeutisches Kombinationspräparat
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN105541727B (zh) * 2016-01-15 2018-01-30 徐州医学院 一种具放疗增敏功能的脂质分子、其制备方法及其在肿瘤放射治疗药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016452B (en) * 1978-02-18 1982-07-21 Kissei Pharmaceutical Imidazole compounds
JPS591415A (ja) * 1982-06-28 1984-01-06 Mochida Pharmaceut Co Ltd 循環系疾患治療剤
GB2229719B (en) * 1989-03-30 1992-04-29 Farmos Oy Novel aromatase inhibiting 4(5)-imidazoles
US5436269A (en) * 1991-11-14 1995-07-25 Sagami Chemical Research Center Method for treating hepatitis
US20020183333A1 (en) * 2000-03-29 2002-12-05 Shah Sudhir V. Compositions and methods for chemotherapy having reduced nephrotoxicity
DE102004052697A1 (de) * 2004-10-29 2006-05-04 Haehner, Thomas, Dr. Pharmazeutische Zubereitungen zur Behandlung von Folgen des Alkoholmissbrauchs, Hepatitis, Pankreatitis, Alzheimererkrankung, Morbus Parkinson, Diabetes, toxischen Nierenerkrankungen, Reperfusionsschäden, der Arteriosklerose sowie als Antidote gegen Umweltgifte und Medikamentenintoxikation

Also Published As

Publication number Publication date
CN101478960B (zh) 2012-06-06
AU2007246023A1 (en) 2007-11-08
RU2477275C1 (ru) 2013-03-10
US8153676B2 (en) 2012-04-10
BRPI0710796A2 (pt) 2011-08-09
HK1134902A1 (en) 2010-05-20
KR101113436B1 (ko) 2012-03-16
DE112007001669A5 (de) 2009-04-16
RU2009113390A (ru) 2010-10-20
JP2009535309A (ja) 2009-10-01
WO2007124734A2 (de) 2007-11-08
CA2650577A1 (en) 2007-11-08
RU2008146974A (ru) 2010-06-10
US20090191262A1 (en) 2009-07-30
CN101478960A (zh) 2009-07-08
AU2007246023B2 (en) 2012-08-16
CA2650577C (en) 2013-01-15
UA93709C2 (ru) 2011-03-10
IL194961A0 (en) 2009-08-03
WO2007124734A3 (de) 2008-02-07
EP2023911B1 (de) 2013-07-03
KR20090023590A (ko) 2009-03-05
EP2023911A2 (de) 2009-02-18
DE102006019906A1 (de) 2007-10-31
RU2446801C2 (ru) 2012-04-10

Similar Documents

Publication Publication Date Title
MX2008013829A (es) Uso de compuestos de la formula a-r-x o sus sales farmaceuticas tolerables para producir una preparacion farmaceutica.
El-Kashef et al. Sitagliptin ameliorates thioacetamide-induced acute liver injury via modulating TLR4/NF-KB signaling pathway in mice
JP2005520778A5 (es)
US11058701B2 (en) Cytarabine conjugates for cancer therapy
JP2018513188A5 (es)
JP2009531450A5 (es)
Jin et al. Pulmonary delivery of the Kv1. 3-blocking peptide HsTX1 [R14A] for the treatment of autoimmune diseases
Aljuffali et al. The codrug approach for facilitating drug delivery and bioactivity
WO2006060731A3 (en) Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
US10919878B2 (en) MCT4 inhibitors and uses thereof
US20080194519A1 (en) Topiramate compositions and methods for their use
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
EP1202737A2 (en) Antiviral therapy use of p-glycoprotein modulators
Kinsell et al. Insulin-sparing sulfonamides
Tepel N-Acetylcysteine in the prevention of ototoxicity
WO2006045298A3 (de) Behandlung von folgen des alkoholmissbrauchs, hepatitis, pankreatitis
MacPherson et al. Propofol and remifentanil total intravenous anesthesia for a patient with Huntington disease
US20210361598A1 (en) Compounds for prevention and treatment of post-intensive care cognitive dysfunction and cognitive dysfunction resulting from respiratory distress
Galinski et al. Reduction of paracetamol metabolism after hepatic resection
WO2007124733A3 (de) Verwendung von substituierten glycerinderivaten zur herstellung einer pharmazeutischen zubereitung
US20150080348A1 (en) Compositions And Methods For Amelioration And Prevention Of Drug-Induced Toxicity
Kumar et al. Prodrugs: Harnessing chemical modifications for improved therapeutics
US20110217364A1 (en) Conjugated suramin amino compounds for medical conditions
Chávez et al. Are N-Acetylcysteine and Resveratrol Effective Treatments for Liver Disease?
Song et al. HCC: A Multicenter, Add-on Randomized Controlled Trial of Adriamycin for Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma

Legal Events

Date Code Title Description
FG Grant or registration